This BRCA Mutation-Positive Ovarian Cancer market study offers a comprehensive analysis of the business models, key strategies, and respective market shares of some of the most prominent players in this landscape. Along with an in-depth commentary on the key influencing factors, market statistics in terms of revenues, segment-wise data, region-wise data, and country-wise data are offered in the full study. This study is one of the most comprehensive documentation that captures all the facets of the evolving BRCA Mutation-Positive Ovarian Cancer market.
A patient with high grade serious ovarian cancer who carry germline mutations in BRCA 1/2 genes is known as BRCA mutation-positive ovarian cancer. BRCA gene mutations lead to a majority of ovarian and breast cancer cases globally. Genetic screening for BRCA mutations in patients has helped researchers for improved preventive measures and therapeutic development. According to CDC data, In U.S. nearly 70,000 new patients suffer from ovarian cancer every year. Most patients are diagnosed at advance stages making it difficult to treat them.
BRCA Mutation-Positive Ovarian Cancer Market: Drivers and Restraints
Increasing incidence of ovarian cancers with BRCA mutations globally is expected to drive the BRCA mutation-positive ovarian cancer market. Advanced and early genetic screening of BRCA mutations in general population will drive the BRCA mutation-positive ovarian cancer market. However, high costs involved in genetic screening and low availability of geneticists may hamper growth of BRCA mutation-positive ovarian cancer market in future.
Market Growth Analysis
Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.
BRCA Mutation-Positive Ovarian Cancer Market: Overview
The global BRCA mutation-positive ovarian cancer market is estimated to show rapid growth over forecast period owing to increasing cases of ovarian cancer in females. BRCA mutation-positive ovarian cancer market has high potential due to development of latest drugs in near future for treating ovarian cancer. In addition, oral contraceptives are used as an adjuvant therapies in the BRCA mutation-positive ovarian cancer market. In 2017, FDA approved tablet form of Olaparib by Astrazeneca, which is used for maintenance treatment of ovarian cancer.
BRCA Mutation-Positive Ovarian Cancer Market: Regional Overview
The global BRCA mutation-positive ovarian cancer market is expected to be dominated by North America due to availability of reimbursements. Latin America market is emerging in BRCA mutation-positive ovarian cancer market due to increasing governmental spending on healthcare. Europe market is expected to be the second most growing region in the global BRCA mutation-positive ovarian cancer market owing to latest research and developmental activities. BRCA mutation-positive ovarian cancer market in East Asia and South Asia is expected to show significant growth due to improving healthcare infrastructure. Middle East and Africa Market is expected to be least lucrative region in the BRCA mutation-positive ovarian cancer market due to poor healthcare facilities and less disease screening facilities.
BRCA Mutation-Positive Ovarian Cancer Market: Key Players
Examples of some of the market participants in BRCA Mutation-Positive Ovarian Cancer market identified across the value chain includes Astrazeneca plc, Merck & Co., Inc., Glaxosmithkline plc, Clovis Oncology, AbbVie Inc., Bristol Myers Squibb Company, Eli Lilly and Company, Johnson & Johnson, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd, and, others.
The research report on BRCA mutation-positive ovarian cancer market presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and, statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report on BRCA mutation-positive ovarian cancer market provides analysis and information according to market segments such as geographies, application, and end user.
The report covers exhaust analysis on BRCA Mutation-Positive Ovarian Cancer Market:
- Market Segments
- Market Dynamics
- Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies involved
- Value Chain
Report on BRCA Mutation-Positive Ovarian Cancer Market includes regional analysis:
- North America (U.S., Canada)
- Latin America (Brazil, Mexico, Argentina)
- Europe (Germany, Italy, France, U.K, Spain, Russia)
- East Asia (China, Japan, South Korea)
- South Asia (India, ASEAN)
- Oceania (Australia, New Zealand)
- Middle East and Africa (GCC Countries, South Africa, Northern Africa)
The report on BRCA mutation-positive ovarian cancer market is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Unique Requirements? Customize this Report
- Customize by Region, Country, Application, Product, & other segments
- Integrate our Insights with your Existing Data
- Determine the scope of the study to suit your requirements
Let FMI Help You!
- Gain Insights on Key BRCA Mutation-Positive Ovarian Cancer Market Impacting Forces
- Know the Winning Strategies of Market Leaders
- Get Deep-Dive Analysis on Each Segment
- Identify the Sources that will Drive Top-Line Revenue
BRCA Mutation-Positive Ovarian Cancer Market: Segmentation
The global BRCA mutation-positive ovarian cancer market is classified on the basis of indication, treatment type, and end user.
Based on indication, BRCA mutation-positive ovarian cancer market is segmented into the following:
- BRCA 1 Ovarian Cancer
- BRCA 2 Ovarian Cancer
Based on treatment type, BRCA mutation-positive ovarian cancer market is segmented into the following:
- Targeted Therapies
- Anti-Angiogenic Agents
- Poly ADP Ribose Polymerase (PARP) inhibitors
Based on end user, BRCA mutation-positive ovarian cancer market is segmented into the following:
- Hospital Pharmacies
- Drug Stores
- Retail Pharmacies
- Online Pharmacies
Report on BRCA Mutation-Positive Ovarian Cancer Market highlights:
- Detailed overview of parent market
- Changing market dynamics in the industry
- In-depth market segmentation
- Historical, current, and projected market size in terms of volume and value
- Recent industry trends and developments
- Competitive landscape
- Strategies of key players and products offered
- Potential and niche segments, geographical regions exhibiting promising growth
- A neutral perspective on market performance
- Must-have information for market players to sustain and enhance their market footprint
Frequently Asked Questions
Why choose FMI?
- With a global presence and a trusted partner to several Fortune 500 firms, FMI covers 1 billion+ data points to build a diversified portfolio for market benchmarking
- Market Reports researched and peer reviewed by industry experts from across the globe
- We follow a multi-dimensional method of analysis monitoring a three-layer data validation process
- In addition to demand-side market assessment, our data triangulation methodology involves supply-side research
- Primary research includes mandatory field interviews with stakeholders involved
- Customizing reports according to client specification is also our forte
What will you discover from BRCA Mutation-Positive Ovarian Cancer Market report?
- The current and future market size, covering each aspect and nuanced trends across key national and geographic markets
- An overview of the market report, providing an imperative visual of the varied market subdivisions and overall forecast statistics in terms of value and volume
- Extensive database and key dynamics elevating the market with varied verticals associated
- Underlying BRCA Mutation-Positive Ovarian Cancer Market forces that are compelling consumers or businesses to purchase the product
- How novel technologies and consumer-centric innovations will create new value-adding opportunities for companies active in the BRCA Mutation-Positive Ovarian Cancer Market
- What will be environment and regulatory impacts on the market over the next decade
Which framework has been used to develop the BRCA Mutation-Positive Ovarian Cancer Market report?
- Investment Feasibility Matrix - It shows returns on investment, level of competition, success rate of investment, and potential risks associated with the market. The analysis shows that the competition is high in the established market, while the returns for short-term investment are also taken into consideration
- Relative Maturity Mapping – The relative maturity is measured according to three growth phases (growth, maturity, decline)
- Relative PLC (Product Life Cycle) – Analysis of the emergence of prominent players and competitive test prices which are driving factors behind every market. (expected market behavior, observed market behavior, expected market performance, observed market performance)